Navamedic ASA: Steady performance and continued product launch in Q1 2026

23 Apr 2026 07:00 CEST

Oslo, 23 April 2026 - In the first quarter of 2026, Navamedic ASA delivered
revenues of NOK 137.9 million, representing a 4.5 per cent increase compared to
the same period last year. Gross margin for the quarter was 39.5 per cent,
compared to 40.7 per cent in Q1 2025. Adjusted EBITDA amounted to NOK 12.5
million, compared to the NOK 12.8 million reported in the first quarter of
2025.

The growth in the quarter was driven by the Prescription Drugs business area,
which saw revenues rise to NOK 76.9 million from NOK 65.0 million in Q1 2025.
This increase was attributable to the addition of NOK 14.3 million from the
Addiction portfolio acquired in July 2025, which was partly offset by lower
sales of Mysimba in particular. The company continued to launch Flexilev® in
OraFID® for advanced Parkinson's care, underscoring its commitment to public
health.

Hospital revenues amounted to NOK 32.0 million, down from NOK 33.1 million in
the same quarter last year, mainly due to marginally lower revenue for
antibiotics and medical nutrition resulting from normal demand fluctuations.

Consumer Health revenue decreased to NOK 29.0 million from NOK 33.9 million,
reflecting a combination of factors, including increased competition and fewer
pharmacy campaigns for Modifast.

"We have had growth in the first quarter of 2026, supported by our strategic
acquisition of the Addiction portfolio. While market conditions remain
competitive, particularly for obesity products, our diversified portfolio and
focus on operational efficiency position us well for the coming quarters. We
will continue to seek opportunities to expand our product offering and
strengthen our gross margins," says Kathrine Gamborg Andreassen, CEO of
Navamedic.

For 2026, modest revenue growth is expected, as full-year contribution from the
Addiction portfolio and the launch of Flexilev in OraFID will be partly offset
by phase-out of selected brands and impact of competition in the obesity market.
Gross margins are expected to improve moderately with a more favourable product
mix. Combined with disciplined cost management, this is anticipated to
positively impact EBITDA.

Presentation and webcast

CEO Kathrine Gamborg Andreassen and CFO Nils Ole Krekling will present the
results today at 08:30 CEST at Haakon VIIs gate 2, Oslo, Norway. The
presentation will be streamed live and available on demand via the following
link: https://navamedic.com/investors/

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, mobile: +47 951 78 680
Nils Ole Krekling, CFO, mobile: +47 924 24 016

About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in Greece.
Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

671241_Navamedic_ASA_2026_Q1_Report.pdf
671241_Navamedic_ASA_2026_Q1_Presentation.pdf